Sabril®

Lundbeck LLC · FDA-approved active Small molecule

Sabril® is a GABA transaminase inhibitor Small molecule drug developed by Lundbeck LLC. It is currently FDA-approved for Infantile spasms (West syndrome), Refractory focal seizures as adjunctive therapy. Also known as: Vigabatrin.

Sabril (vigabatrin) irreversibly inhibits GABA transaminase, the enzyme that breaks down the neurotransmitter GABA, thereby increasing GABA levels in the brain.

Sabril (vigabatrin) irreversibly inhibits GABA transaminase, the enzyme that breaks down the neurotransmitter GABA, thereby increasing GABA levels in the brain. Used for Infantile spasms (West syndrome), Refractory focal seizures as adjunctive therapy.

At a glance

Generic name	Sabril®
Also known as	Vigabatrin
Sponsor	Lundbeck LLC
Drug class	GABA transaminase inhibitor
Target	GABA transaminase (ABAT)
Modality	Small molecule
Therapeutic area	Neurology
Phase	FDA-approved

Mechanism of action

By inhibiting GABA transaminase, vigabatrin prevents the degradation of GABA, leading to sustained elevation of this inhibitory neurotransmitter in the central nervous system. This enhanced GABAergic inhibition reduces neuronal excitability and seizure activity. The mechanism is irreversible, meaning the enzyme inhibition persists until new enzyme is synthesized.

Approved indications

• Infantile spasms (West syndrome)
• Refractory focal seizures as adjunctive therapy

Common side effects

• Visual field defects
• Fatigue
• Somnolence
• Weight gain
• Peripheral edema
• Headache

Key clinical trials

• Acceptability Study of a New Paediatric Form of Vigabatrin in Infants and Children With Infantile Spasms or Pharmacoresistant Partial Epilepsy (NA)
• Sabril Patient Registry
• A Study of the Structure and Function of the Retina in Adult Patients With Refractory Complex Partial Seizures Treated With Vigabatrin (Sabril®) (PHASE4)
• Clinical and Economic Burden of Uncontrolled Epilepsy: Analyses From a Medicaid Database and a Private Health Plan Database
• An Open-Label, Single and Multiple Oral Dose Pharmacokinetic Study of Vigabatrin in Infants With Infantile Spasms (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Sabril® CI brief — competitive landscape report
• Sabril® updates RSS · CI watch RSS
• Lundbeck LLC portfolio CI

Frequently asked questions about Sabril®

What is Sabril®?

Sabril® is a GABA transaminase inhibitor drug developed by Lundbeck LLC, indicated for Infantile spasms (West syndrome), Refractory focal seizures as adjunctive therapy.

How does Sabril® work?

Sabril (vigabatrin) irreversibly inhibits GABA transaminase, the enzyme that breaks down the neurotransmitter GABA, thereby increasing GABA levels in the brain.

What is Sabril® used for?

Sabril® is indicated for Infantile spasms (West syndrome), Refractory focal seizures as adjunctive therapy.

Who makes Sabril®?

Sabril® is developed and marketed by Lundbeck LLC (see full Lundbeck LLC pipeline at /company/lundbeck-llc).

Is Sabril® also known as anything else?

Sabril® is also known as Vigabatrin.

What drug class is Sabril® in?

Sabril® belongs to the GABA transaminase inhibitor class. See all GABA transaminase inhibitor drugs at /class/gaba-transaminase-inhibitor.

What development phase is Sabril® in?

Sabril® is FDA-approved (marketed).

What are the side effects of Sabril®?

Common side effects of Sabril® include Visual field defects, Fatigue, Somnolence, Weight gain, Peripheral edema, Headache.

What does Sabril® target?

Sabril® targets GABA transaminase (ABAT) and is a GABA transaminase inhibitor.

Related

• Drug class: All GABA transaminase inhibitor drugs
• Target: All drugs targeting GABA transaminase (ABAT)
• Manufacturer: Lundbeck LLC — full pipeline
• Therapeutic area: All drugs in Neurology
• Indication: Drugs for Infantile spasms (West syndrome)
• Indication: Drugs for Refractory focal seizures as adjunctive therapy
• Also known as: Vigabatrin